Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dos…

- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 … [+21114 chars]
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - FHMnews